【摘要】 目的 探寻重组人尿激酶对急性ST段抬高型心肌梗死的临床疗效及对炎症因子的影响。方法 选择本院2016年4月至2020年12月收治的急性ST段抬高型心肌梗死患者90例，按随机数字表法分成两组，各45例。对照组采取常规治疗，观察组在对照组基础上给予重组人尿激酶治疗，比较两组治疗效果。结果 观察组治疗总有效率高于对照组（P <0.05）；治疗后观察组超敏C-反应蛋白（hs-CRP）值低于对照组，D-二聚体值高于对照组（P <0.05）；观察组心血管不良事件发生率低于对照组（P <0.05）。结论 重组人尿激酶对急性ST段抬高型心肌梗死的临床疗效显著，能显著减轻炎症反应，降低心血管不良事件发生率。更多还原

【Abstract】 Objective To explore the clinical effect of recombinant human urokinase on acute ST-segment elevation myocardial infarction and its effect on inflammatory factors. Methods 90 patients with acute ST-segment elevation myocardial infarction received in our hospital from April 2016 to December 2020 were randomly divided into two groups, 45 cases in each group.The control group was treated with routine treatment, and the observation group was treated with recombinant human urokinase on the basis of the control group. The therapeutic effects of the two groups were compared. Results The total effective rate of the observation group was higher than that of the control group(P<0.05); After treatment, the value of hs-CRP in the observation group was lower than that in the control group, and the value of D-dimer was higher than that in the control group(P<0.05);The incidence of cardiovascular adverse events in the observation group was lower than that in the control group(P<0.05).Conclusion Recombinant human urokinase has a significant clinical effect on acute ST-segment elevation myocardial infarction,which can significantly reduce the inflammatory reaction and the incidence of cardiovascular adverse events.更多还原